drugset / Trial / NCT02348918
Phase 2 Randomized Clinical Trial of Luminate® as Compared to Avastin® in the Treatment of Diabetic Macular Edema
Phase 2
Completed
218 enrolled
Allegro Ophthalmics, LLC
Duke University · collabTrial Runners, LLC · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
A Phase 2 Multi center, Randomized, Controlled, Double-Masked Clinical Trial Designed To Evaluate The Safety And Exploratory Efficacy Of Luminate® (Alg-1001) As Compared To Avastin® In The Treatment Of Diabetic Macular Edema
Timeline
- Start
- 2014-10-13
- Primary completion
- 2017-05-16
- Completion
- 2017-06-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Bevacizumab | Monoclonal antibody | 1.25 mg | Intravitreal |
| Comparator | Risuteganib | Protein / enzyme biologic | 0.5 mg | Intravitreal |
| Comparator | Risuteganib | Protein / enzyme biologic | 1 mg | Intravitreal |
| Comparator | Risuteganib | Protein / enzyme biologic | 2 mg | Intravitreal |
| Comparator | Risuteganib | Protein / enzyme biologic | 3 mg | Intravitreal |